LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Amgen Inc. (“Amgen” or the “Company”) (Nasdaq: AMGN).
If you purchased or otherwise acquired Amgen shares, and would like more information regarding the investigation, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you.
The investigation focuses on whether Amgen and certain of its officers and/or directors violated federal securities laws. On May 22, 2017, the Company revealed that its osteoporosis medicine, Evenity, raised concerns about heart safety that will lead to a delay in securing approval in the United States. According to data disclosed by Amgen, a higher percentage of patients who took the drug suffered serious cardiovascular side effects after a year, than those who took an older approved medicine. When this news was announced, Amgen’s stock price fell.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.